Abstract

Traditional drug delivery methods aimed for a consistent or sustained medication output to maximize treatment efficacy while minimizing side effects. These dosage forms release medications in a controlled or varied manner. Illnesses are treated by administering drugs to patients in a variety of traditional dose patterns. All these dosage patterns should always be administered monotonously for retaining the drug concentration in a therapeutically effective spectrum. Chronotherapeutics, a type of drug delivery system, has become increasingly important in the treatment of chronic diseases in recent years. Today's environment necessitates chronopharmaceutical formulations that increase patient compliance, optimize medicine distribution at the target site, and minimize side effects to reduce mortality rates. A mechanism in which a medicament has been distributed rapidly after a specified lag interval or time gap in compliance with the circadian rhythm of sickness conditions is known as pulsative drug release. Pulsatile medication delivery is becoming more prevalent these days. The main benefit of this method of the medication delivery system is that the substance is only aired when it is required. Because of this, the risk of developing drug resistance, which is common in both preparations for both conventional and sustained release, is minimized. In addition, certain anticancer medications are quite hazardous. In both traditional and sustained release therapy, these medicines cause serious complications. There are now a plethora of FDA-approved chronotherapeutic medications on the market. This treatment is most useful when a long-term effect is just not necessary and medications are harmful. The most important aspect of this formulation's development is determining the circadian rhythm or an appropriate criterion that would set off the drug's release.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call